Clinical Trials Sponsored by AstraZeneca, Bristol-Myers Squibb

Total 2661 results

AstraZeneca
AstraZeneca, Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

China, Korea, Republic of, India
AstraZeneca
Bristol-Myers Squibb

Completed

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Type 2 Diabetes

Korea, Republic of, United States, Mexico, Puerto Rico, Philippines, Russian Federation, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1)

Type 1 Diabetes Mellitus

United States, Austria, Germany, Italy, Spain, United Kingdom, Belgium, Mexico, Israel, Hungary, Canada, Australia, Denmark, Sweden, Romania, France, Finland
AstraZeneca
Bristol-Myers Squibb

Completed

Phase III Insulin Add-On Asia Regional Program - ST

Diabetes

China, Korea, Republic of, Singapore
AstraZeneca
Bristol-Myers Squibb

Completed

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada
AstraZeneca
Bristol-Myers Squibb

Completed

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Canada, Mexico, India, Puerto Rico, Russian Federation, South Africa
AstraZeneca
Bristol-Myers Squibb

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2

United States, Mexico, Canada, United Kingdom, India, Belgium, Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Diabetes Mellitus, Type 2

Australia, United States, Italy, Argentina, Canada, Mexico, India, Peru, Spain, Denmark, France, Singapore, Puerto Rico
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Type 2 Diabetes

Mexico, Russian Federation, Spain, United States, Canada, Puerto Rico, Hungary, Peru, Romania, Poland, Germany, Czech Republic, India, Colombia, Denmark, Finland
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Type 2 Diabetes

Australia, United States, Canada, Mexico, Puerto Rico, Germany, Hungary, Ireland, Poland, Romania, Denmark, Czech Republic, India, Colombia, Finland, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Drug Interaction With Metformin

Healthy Male and Female Subjects

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca
Bristol-Myers Squibb

Terminated

Renal Mechanism of Action/Splay vs. TmG (MOA)

Diabetes, NOS

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
AstraZeneca
Bristol-Myers Squibb

Completed

To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Dapagliflozin Taken Twice-daily

Type 2 Diabetes

South Africa, Germany, Hungary, Romania, Slovakia, Switzerland, Ukraine
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin DPPIV Inhibitor add-on Study

Type 2 Diabetes

United States, Germany, Poland, Argentina, United Kingdom, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration (SAXA)

Type 2 Diabetes Mellitus(T2DM)

China
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Hypertension | Cardiovascular Disease | Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Vietnam, Germany, Romania, Canada, Argentina, Slovakia, Taiwan, Spain
AstraZeneca
Bristol-Myers Squibb

Completed

Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

Type 2 Diabetes

Russian Federation
AstraZeneca
Bristol-Myers Squibb

Completed

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Healthy Volunteers

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Type 2 Diabetes

Korea, Republic of, Russian Federation, United Kingdom, Vietnam, Germany, Hungary, Finland, Norway, Netherlands, Slovakia, India
AstraZeneca
Bristol-Myers Squibb

Completed

Effects of Single Oral Dose Dapagliflozin QT Study

Healthy

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, China, India
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of, Philippines, China, India
AstraZeneca
AstraZeneca, Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

China, Korea, Republic of, Taiwan, India
AstraZeneca
Bristol-Myers Squibb

Completed

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Mexico, Puerto Rico
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Type 2 Diabetes Mellitus (T2DM)

United States
AstraZeneca
Bristol-Myers Squibb

Terminated

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

Mexico, United States, Argentina, Brazil, Canada
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control | High HbA1c Level

Czech Republic, Poland, Spain, Germany, Canada, Slovakia
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Bulgaria, Poland, Hungary, Argentina, Australia, Austria, Canada, Germany, Chile
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Bulgaria, Czech Republic, Hungary, Poland
AstraZeneca
Bristol-Myers Squibb

Completed

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Healthy Volunteers

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

Healthy

Sweden
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control

Type 2 Diabetes

India
AstraZeneca
Bristol-Myers Squibb

Terminated

Evaluation of Diabetes Care at Austrian GPs (DCA09)

Type 2 Diabetes
AstraZeneca
Bristol-Myers Squibb

Completed

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2)

Type 1 Diabetes Mellitus

United States, Germany, Belgium, Canada, Japan, Chile, United Kingdom, Poland, Netherlands, Argentina, Sweden, Russian Federation, Switzerland
AstraZeneca
Bristol-Myers Squibb

Completed

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Mexico
AstraZeneca
Bristol-Myers Squibb

Completed

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
AstraZeneca
Bristol-Myers Squibb

Completed

Renal Impairment in Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

Diabetes Mellitus, Type 2

Argentina
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects (ULDS)

Type 2 Diabetes

United States

Clinical Trials Sponsored by AstraZeneca, Bristol-Myers Squibb

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations